ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

taletrectinib

Also written as “Taletrectinib”, “AB-106” and “DS6051b”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasms, led by 2 companies.

Drug pageTaletrectinib: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 12, 202411 company-led studies, 5 open or runningNext primary completion: Feb 2, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nuvation Bioits history only105 open or runningphase 3since Aug 12, 2024Oct 15, 2014Feb 2, 2027phase 1 · NCT07742384
Daiichi Sankyo10 open or runningphase 1since Feb 2, 2016Feb 2, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Daiichi Sankyo only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 2, 2016First study: phase 1 study in Advanced Solid Malignant TumorsFirst studyNCT02675491 · 15 enrolled · Japan
  2. Jun 9, 2020Named taletrectinibINNProposed as its International Nonproprietary Name in WHO's List 123 · before, AB-106

TargetBeta

“An orally available inhibitor of the receptor tyrosine kinases C-ros oncogene 1 (ROS1) and the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, ”NCIt, by rule
“Proto-oncogene tyrosine-protein kinase ROS inhibitor; Neurotrophic tyrosine kinase receptor inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
repotrectinibruleBristol-Myers Squibbphase 39

Studies

The one study Daiichi Sankyo leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02675491Advanced Solid Malignant Tumors · Japan1CompletedDec 27, 202115

How it is read

Names in the registry

  • “Taletrectinib”, 5 entries
  • “AB-106”, 2 entries
  • “DS6051b”, 1 entry
  • “DS-6051b”, 1 entry
  • “AB-106, Itraconazole”, 1 entry

Codes read as this program: AB106.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.